J. Moran

发表

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples

I. Chaudhary, N. Damle, E. Boghaert, 2008, Cancer Chemotherapy and Pharmacology.

Optimization of urinary FDG excretion during PET imaging.

M. Blaufox, H. Lee, J. Moran, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Protonation and stability constants for the complexation of K+, Rb+ and Cs+ with 5, 11, 17, 23, 29, 35-hexakis-tert-butyl-37, 39, 41-trimethoxy-38, 40, 42-tris-oxoacetic acid calix[6]arene

J. Bollinger, D. Roundhill, J. Moran, 1994 .

New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor.

G. Denardo, S. Denardo, C. Meares, 1998, Hybridoma.

New and Future Trends in Radiopharmaceuticals

M. Blaufox, J. Moran, 1999 .

Production and Characterization of Chemically Inactivated Genetically Engineered Clostridium difficile Toxoids.

P. Cai, H. Yuan, J. Lotvin, 2016, Journal of pharmaceutical sciences.

Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC.

Virgil L. Woods, K. Parris, L. Mosyak, 2013, Journal of molecular biology.

Improved synthesis of 6-[p-(bromoacetamido)benzyl]-1,4,8,11-tetraazacyclotetradecane- N,N',N",N"-tetraacetic acid and development of a thin-layer assay for thiol-reactive bifunctional chelating agents.

C. Meares, D. P. Greiner, J. Moran, 1995, Bioconjugate chemistry.

New approaches to delivering metal-labeled antibodies to tumors : Synthesis and characterization of new biotinyl chelate conjugates for pre-targeted diagnosis and therapy

C. Meares, V. Jacques, D. Goodwin, 1996 .

NMR structural analysis of the capsular polysaccharide from Streptococcus pneumoniae serotype 6C.

P. Cai, J. Moran, V. Pavliak, 2012, Carbohydrate research.

INTRODUCTION OF BRIDGING ETHYL PHOSPHATE SUBSTITUENTS ONTO THE LOWER RIM OF CALIX[6]ARENES

D. Roundhill, J. Moran, 1992 .

Introduction of diphenylphosphinite functional groups onto selected positions on the lower rim of calix[4]arenes and calix[6]arenes

D. Roundhill, J. Moran, 1992 .

Synthesis and Structural Characterization of Calix[4]arenes, Calix[6]arenes, and Calix[8]arenes with 3-Hydroxypropoxy or 2-Hydroxyethoxy Functional Groups Appended onto the Lower Rim

J. Mague, D. Roundhill, A. Yordanov, 1994 .

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

N. Damle, E. Boghaert, J. Dijoseph, 2006, Clinical Cancer Research.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Boris Gorovits, P. Frost, S. Stephens, 2004, Blood.

Technetium-99m-EC and other potential new agents in renal nuclear medicine.

J. Moran, 1999, Seminars in nuclear medicine.

Synthesis of the protein cutting reagent iron (S)-1-(p-bromoacetamidobenzyl)ethylenediaminetetraacetate and conjugation to cysteine side chains.

A. Ishihama, C. Meares, A. D. Jones, 1997, Bioconjugate chemistry.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

P. Frost, S. Stephens, N. Damle, 2004, Blood.

Improved Synthesis of 6‐(p‐(Bromoacetamido)benzyl)‐1,4,8,11‐ tetraazacyclotetradecane‐N,N′,N′′,N′′′‐tetraacetic Acid (I) and Development of a Thin‐Layer Assay for Thiol‐Reactive Bifunctional Chelating Agents.

C. Meares, D. P. Greiner, J. Moran, 1995 .